NCO-48 Fumarate
Alternative Names: NCO 48; NCO-1010; NCO48 Fumarate; NUC-1010; Teneofovir prodrug - Nucorion PharmaceuticalsLatest Information Update: 28 Apr 2023
At a glance
- Originator Nucorion Pharmaceuticals
- Developer Ligand Pharmaceuticals; Nucorion Pharmaceuticals
- Class Adenine nucleotides; Antivirals; Phosphonic acids; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Hepatitis-B in USA (PO)
- 28 Dec 2022 Nucorion Pharmaceuticals in collaboration with Ligand Pharmaceuticals completes a phase I trial for Hepatitis B in USA (PO) (NCT04629976)
- 04 Nov 2022 Pharmacokinetics and adverse events data from a phase I trial in Hepatitis B presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)